GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Cyclically Adjusted Price-to-FCF

CAMRF (Camurus AB) Cyclically Adjusted Price-to-FCF : (As of Jun. 25, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Camurus AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Camurus AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Cyclically Adjusted Price-to-FCF Chart

Camurus AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Camurus AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Camurus AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Camurus AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Camurus AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Camurus AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Camurus AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Camurus AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.072/132.8245*132.8245
=0.072

Current CPI (Mar. 2025) = 132.8245.

Camurus AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.059 99.995 0.078
201509 -0.071 100.228 -0.094
201512 0.113 100.276 0.150
201603 -0.425 100.751 -0.560
201606 -0.077 101.019 -0.101
201609 -0.090 101.138 -0.118
201612 -0.027 102.022 -0.035
201703 -0.122 102.022 -0.159
201706 -0.170 102.752 -0.220
201709 -0.131 103.279 -0.168
201712 -0.158 103.793 -0.202
201803 -0.151 103.962 -0.193
201806 -0.218 104.875 -0.276
201809 -0.210 105.679 -0.264
201812 -0.174 105.912 -0.218
201903 -0.236 105.886 -0.296
201906 -0.257 106.742 -0.320
201909 -0.184 107.214 -0.228
201912 -0.241 107.766 -0.297
202003 -0.126 106.563 -0.157
202006 -0.134 107.498 -0.166
202009 -0.070 107.635 -0.086
202012 -0.159 108.296 -0.195
202103 -0.128 108.360 -0.157
202106 -0.091 108.928 -0.111
202109 -0.009 110.338 -0.011
202112 -0.079 112.486 -0.093
202203 -0.016 114.825 -0.019
202206 0.016 118.384 0.018
202209 0.086 122.296 0.093
202212 0.075 126.365 0.079
202303 0.037 127.042 0.039
202306 0.101 129.407 0.104
202309 0.760 130.224 0.775
202312 0.047 131.912 0.047
202403 0.056 132.205 0.056
202406 0.155 132.716 0.155
202409 0.235 132.304 0.236
202412 0.127 132.987 0.127
202503 0.072 132.825 0.072

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Camurus AB  (OTCPK:CAMRF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Camurus AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Camurus AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Industry
Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.